TY  - JOUR
AU  - Forget, Antoine
AU  - Martignetti, Loredana
AU  - Puget, Stéphanie
AU  - Calzone, Laurence
AU  - Brabetz, Sebastian
AU  - Picard, Daniel Joseph
AU  - Montagud, Arnau
AU  - Liva, Stéphane
AU  - Sta, Alexandre
AU  - Dingli, Florent
AU  - Arras, Guillaume
AU  - Rivera, Jaime
AU  - Loew, Damarys
AU  - Besnard, Aurore
AU  - Lacombe, Joëlle
AU  - Pagès, Mélanie
AU  - Varlet, Pascale
AU  - Dufour, Christelle
AU  - Yu, Hua
AU  - Mercier, Audrey L
AU  - Indersie, Emilie
AU  - Chivet, Anaïs
AU  - Leboucher, Sophie
AU  - Sieber, Laura
AU  - Beccaria, Kevin
AU  - Gombert, Michael
AU  - Meyer, Frauke-Dorothee
AU  - Qin, Nan
AU  - Bartl, Jasmin
AU  - Chavez, Lukas
AU  - Okonechnikov, Konstantin
AU  - Sharma, Tanvi
AU  - Thatikonda, Venu
AU  - Bourdeaut, Franck
AU  - Pouponnot, Celio
AU  - Ramaswamy, Vijay
AU  - Korshunov, Andrey
AU  - Borkhardt, Arndt
AU  - Reifenberger, Guido
AU  - Poullet, Patrick
AU  - Taylor, Michael D
AU  - Kool, Marcel
AU  - Pfister, Stefan
AU  - Kawauchi, Daisuke
AU  - Barillot, Emmanuel
AU  - Remke, Marc
AU  - Ayrault, Olivier
TI  - Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling.
JO  - Cancer cell
VL  - 34
IS  - 3
SN  - 1535-6108
CY  - Cambridge, Mass.
PB  - Cell Press
M1  - DKFZ-2018-01521
SP  - 379 - 395.e7
PY  - 2018
AB  - The current consensus recognizes four main medulloblastoma subgroups (wingless, Sonic hedgehog, group 3 and group 4). While medulloblastoma subgroups have been characterized extensively at the (epi-)genomic and transcriptomic levels, the proteome and phosphoproteome landscape remain to be comprehensively elucidated. Using quantitative (phospho)-proteomics in primary human medulloblastomas, we unravel distinct posttranscriptional regulation leading to highly divergent oncogenic signaling and kinase activity profiles in groups 3 and 4 medulloblastomas. Specifically, proteomic and phosphoproteomic analyses identify aberrant ERBB4-SRC signaling in group 4. Hence, enforced expression of an activated SRC combined with p53 inactivation induces murine tumors that resemble group 4 medulloblastoma. Therefore, our integrative proteogenomics approach unveils an oncogenic pathway and potential therapeutic vulnerability in the most common medulloblastoma subgroup.
LB  - PUB:(DE-HGF)16
C6  - pmid:30205043
DO  - DOI:10.1016/j.ccell.2018.08.002
UR  - https://inrepo02.dkfz.de/record/137641
ER  -